Comparison of Colorectal Cancer Stem Cells and Oxaliplatin-Resistant Cells Unveils Functional Similarities

Overview

Journal Cells

Publisher MDPI

Specialties Biochemistry
Biophysics
Cell Biology
Molecular Biology

Date 2022 Feb 15

PMID 35159320

Authors

Vanessa Rodriguez-Fanjul

Rosa Guerrero-Lopez

Beatriz Fernandez-Varas

Rosario Perona

Ana Sastre-Perona

Leandro Sastre

Affiliations

Soon will be listed here.

Abstract

Colorectal cancer is the second most common cancer in women, the third in men, and an important cause of cancer-related mortality. Recurrence and the development of chemotherapy resistance are major hindrances for patients' treatment. The presence of cancer stem cells with chemotherapy resistance able to generate proliferating tumor cells contributes to tumor recurrence and resistance. In addition, tumor cells can develop chemoresistance through adaptation mechanisms. In this article, cancer stem cells were isolated from HT29 and SW620 colorectal cancer cell lines. Oxaliplatin resistance was induced by a single drug treatment simulating the usual guidelines of patient treatment. A comparison of these two populations showed similarities since cancer stem cells presented increased oxaliplatin resistance, and resistant cells contained an increased number of cancer stem cells. Cancer stem cells isolated from resistant cells showed increased oxaliplatin resistance. Cell invasion capacity and epithelial-mesenchymal transition were increased both in cancer stem cells and oxaliplatin-resistant cells. mRNA expression analysis showed that both cell types shared a significant proportion of commonly regulated genes. In summary, the data presented indicate that colorectal cancer stem cells and oxaliplatin-resistant cells are highly related cell populations that might have interesting implications in the development of tumor recurrence and resistance to chemotherapy.

Citing Articles

Mapping the intellectual structure and emerging trends on nanomaterials in colorectal cancer: a bibliometric analysis from 2003 to 2024.

Lu M, Liu Y, Zhu J, Shang J, Bai L, Jin Z Front Oncol. 2025; 14():1514581.

PMID: 39845318 PMC: 11750690. DOI: 10.3389/fonc.2024.1514581.

Antibiotic use during radical surgery in stage I-III colorectal cancer: correlation with outcomes?.

Xu M, Chen Y, Li P, Ye Q, Feng S, Yan B BMC Cancer. 2024; 24(1):769.

PMID: 38926655 PMC: 11210026. DOI: 10.1186/s12885-024-12550-w.

The E3 ligase HUWE1 increases the sensitivity of CRC to oxaliplatin through TOMM20 degradation.

Lee C, Park S, Yoon S Oncogene. 2024; 43(9):636-649.

PMID: 38184713 DOI: 10.1038/s41388-023-02928-8.

Oxaliplatin Enhances the Apoptotic Effect of Mesenchymal Stem Cells, Delivering Soluble TRAIL in Chemoresistant Colorectal Cancer.

Quiroz-Reyes A, Delgado-Gonzalez P, Islas J, Soto-Dominguez A, Gonzalez-Villarreal C, Padilla-Rivas G Pharmaceuticals (Basel). 2023; 16(10).

PMID: 37895919 PMC: 10610062. DOI: 10.3390/ph16101448.

Cancer cell cycle heterogeneity as a critical determinant of therapeutic resistance.

Maleki E, Bahrami A, Matin M Genes Dis. 2023; 11(1):189-204.

PMID: 37588236 PMC: 10425754. DOI: 10.1016/j.gendis.2022.11.025.

References

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Siegel R, Miller K, Jemal A . Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1):7-34. DOI: 10.3322/caac.21551. View

Bose D, Zimmerman L, Pierobon M, Petricoin E, Tozzi F, Parikh A . Chemoresistant colorectal cancer cells and cancer stem cells mediate growth and survival of bystander cells. Br J Cancer. 2011; 105(11):1759-67. PMC: 3242606. DOI: 10.1038/bjc.2011.449. View

Blazer 3rd D, Kishi Y, Maru D, Kopetz S, Chun Y, Overman M . Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008; 26(33):5344-51. DOI: 10.1200/JCO.2008.17.5299. View

Xie Y, Chen Y, Fang J . Comprehensive review of targeted therapy for colorectal cancer. Signal Transduct Target Ther. 2020; 5(1):22. PMC: 7082344. DOI: 10.1038/s41392-020-0116-z. View

Thiery J . Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002; 2(6):442-54. DOI: 10.1038/nrc822. View

Scopelliti A, Cammareri P, Catalano V, Saladino V, Todaro M, Stassi G . Therapeutic implications of Cancer Initiating Cells. Expert Opin Biol Ther. 2009; 9(8):1005-16. DOI: 10.1517/14712590903066687. View

Singh A, Settleman J . EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene. 2010; 29(34):4741-51. PMC: 3176718. DOI: 10.1038/onc.2010.215. View

Reya T, Morrison S, Clarke M, Weissman I . Stem cells, cancer, and cancer stem cells. Nature. 2001; 414(6859):105-11. DOI: 10.1038/35102167. View

10.

Lopez-Ayllon B, Moncho-Amor V, Abarrategi A, de Caceres I, Castro-Carpeno J, Belda-Iniesta C . Cancer stem cells and cisplatin-resistant cells isolated from non-small-lung cancer cell lines constitute related cell populations. Cancer Med. 2014; 3(5):1099-111. PMC: 4302662. DOI: 10.1002/cam4.291. View

11.

Stewart C, Warner S, Ito K, Raoof M, Wu G, Kessler J . Cytoreduction for colorectal metastases: liver, lung, peritoneum, lymph nodes, bone, brain. When does it palliate, prolong survival, and potentially cure?. Curr Probl Surg. 2018; 55(9):330-379. PMC: 6422355. DOI: 10.1067/j.cpsurg.2018.08.004. View

12.

Ohata H, Ishiguro T, Aihara Y, Sato A, Sakai H, Sekine S . Induction of the stem-like cell regulator CD44 by Rho kinase inhibition contributes to the maintenance of colon cancer-initiating cells. Cancer Res. 2012; 72(19):5101-10. DOI: 10.1158/0008-5472.CAN-11-3812. View

13.

Bao S, Wu Q, McLendon R, Hao Y, Shi Q, Hjelmeland A . Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756-60. DOI: 10.1038/nature05236. View

14.

Yang A, Fan F, Camp E, Van Buren G, Liu W, Somcio R . Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res. 2006; 12(14 Pt 1):4147-53. DOI: 10.1158/1078-0432.CCR-06-0038. View

15.

Kawamoto H, Yuasa T, Kubota Y, Seita M, Sasamoto H, Shahid J . Characteristics of CD133(+) human colon cancer SW620 cells. Cell Transplant. 2010; 19(6):857-64. DOI: 10.3727/096368910X508988. View

16.

Vishnubalaji R, Manikandan M, Fahad M, Hamam R, Alfayez M, Kassem M . Molecular profiling of ALDH1 colorectal cancer stem cells reveals preferential activation of MAPK, FAK, and oxidative stress pro-survival signalling pathways. Oncotarget. 2018; 9(17):13551-13564. PMC: 5862598. DOI: 10.18632/oncotarget.24420. View

17.

Mani S, Guo W, Liao M, Eaton E, Ayyanan A, Zhou A . The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-15. PMC: 2728032. DOI: 10.1016/j.cell.2008.03.027. View

18.

Sato R, Semba T, Saya H, Arima Y . Concise Review: Stem Cells and Epithelial-Mesenchymal Transition in Cancer: Biological Implications and Therapeutic Targets. Stem Cells. 2016; 34(8):1997-2007. DOI: 10.1002/stem.2406. View

19.

Lou H, Dean M . Targeted therapy for cancer stem cells: the patched pathway and ABC transporters. Oncogene. 2007; 26(9):1357-60. DOI: 10.1038/sj.onc.1210200. View

20.

Francescangeli F, Contavalli P, De Angelis M, Careccia S, Signore M, Haas T . A pre-existing population of ZEB2 quiescent cells with stemness and mesenchymal features dictate chemoresistance in colorectal cancer. J Exp Clin Cancer Res. 2020; 39(1):2. PMC: 6947904. DOI: 10.1186/s13046-019-1505-4. View